IV NAD+ infusions cost $500-1,500 per session. Oral NMN/NR costs $30-60/month. Is injectable NAD+ worth the price? A deep dive into bioavailability, evidence, and practical protocols.
The question of injectable versus oral NAD+ precursors has become one of the most debated topics in longevity medicine, largely because the cost difference is staggering. A single IV NAD+ infusion runs $500-1,500 depending on your location and provider, requires 2-4 hours in a clinical chair, and needs to be repeated regularly. Meanwhile, a month's supply of oral NMN or NR capsules costs $30-60 and takes 30 seconds to swallow each morning. The obvious question is whether the injectable route delivers meaningfully better outcomes to justify a price difference of 10-50x.
The honest answer is: probably not for most people, though the full picture is more nuanced than either camp typically acknowledges.
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in every cell of your body, involved in over 500 enzymatic reactions. It is essential for mitochondrial energy production, DNA repair, sirtuin activation, and cellular stress response. The problem: NAD+ levels decline approximately 50% between ages 40 and 60, and this decline is now recognized as a contributor to virtually every hallmark of aging.
The strategic question is how to restore NAD+ levels most effectively. There are three main approaches:
1. Oral precursors (NMN, NR) that the body converts to NAD+ through metabolic pathways
2. IV infusions that deliver NAD+ directly to the bloodstream
3. Subcutaneous injections of NAD+ or its precursors
For the foundational science on NAD+ and its role in aging, see our NMN/NR intervention page (Limited evidence).
Nicotinamide Mononucleotide (NMN) and Nicotinamide Riboside (NR) are the two most popular oral NAD+ precursors. Both are converted to NAD+ through cellular metabolic pathways, though they enter the pathway at different points.
NR (Nicotinamide Riboside):
NMN (Nicotinamide Mononucleotide):
What oral precursors reliably do:
What remains unproven for oral precursors:
IV NAD+ clinics have proliferated in major cities, often marketed alongside wellness services like IV hydration and vitamin drips. Here is what the infusion process actually involves:
The experience:
The pharmacokinetic reality:
This is where the science becomes inconvenient for IV NAD+ proponents. When NAD+ is delivered directly to the bloodstream, it does achieve very high peak plasma levels, much higher than oral precursors can reach. However, IV NAD+ has a plasma half-life of less than 1 hour. This means that within 4-6 hours of your $1,000 infusion, your blood NAD+ levels have largely returned to baseline.
The counterargument from IV advocates is that the brief supraphysiological spike triggers beneficial cellular responses that persist beyond the NAD+ itself. This is theoretically plausible but unproven. No published clinical trial has demonstrated that intermittent IV NAD+ spikes produce superior long-term outcomes compared to the steady-state elevation achieved by daily oral precursors.
| Factor | Oral NMN/NR | IV NAD+ | Subcutaneous NAD+ |
|--------|------------|---------|-------------------|
| Monthly cost | $30-60 | $2,000-6,000 | $200-500 |
| Time per dose | 30 seconds | 2-4 hours | 5 minutes |
| NAD+ elevation | Moderate, sustained | High peak, brief | Moderate peak, brief |
| Human RCT data | Multiple published | Very limited | Very limited |
| Convenience | High | Very low | Moderate |
| Medical supervision needed | No | Yes | Recommended |
| Pain/discomfort | None | Common (nausea, cramping) | Injection site soreness |
For a 12-month comparison: oral NMN at 500 mg daily costs approximately $360-720 per year. Monthly IV NAD+ infusions cost $6,000-18,000 per year. The question is whether the IV route delivers 10-25x better outcomes. The current evidence says no.
A third option has emerged: subcutaneous NAD+ injections, which can be self-administered at home after initial medical guidance. These deliver NAD+ directly past the gut but avoid the extreme cost and time commitment of IV infusions.
Advantages over IV:
Disadvantages:
It is telling that most prominent longevity researchers who take NAD+ precursors themselves use the oral route:
None of the leading longevity researchers have publicly stated that IV NAD+ is necessary or superior to oral precursors for long-term healthspan benefits.
Despite the general case for oral precursors, there are specific scenarios where IV NAD+ may offer acute benefits:
1. Acute recovery situations (jet lag, illness recovery, intensive athletic events)
2. Initial loading followed by transition to oral maintenance
3. Individuals with severe GI absorption issues that limit oral supplementation
4. Addiction recovery protocols (NAD+ IV has been used in some clinics for this purpose)
These use cases treat IV NAD+ as an acute intervention rather than a maintenance strategy, which is arguably more aligned with its pharmacokinetic profile.
For most people: Daily oral NMN (250-1000 mg) or NR (300-600 mg) provides reliable, sustained NAD+ elevation at a fraction of the cost of IV infusions. Add TMG (trimethylglycine, 500-1000 mg) to support methylation, and take it in the morning for optimal circadian alignment.
If considering IV NAD+: Understand that you are paying a significant premium for an unproven advantage. The brief supraphysiological spike has theoretical appeal but no demonstrated superiority over daily oral supplementation in published clinical trials.
Quality matters regardless of route:
The injectable NAD+ industry has grown faster than the evidence supporting it. While IV NAD+ clinics provide a real service and the compound is genuinely important for cellular health, the current data does not justify the 10-50x cost premium over daily oral NMN or NR for long-term longevity purposes. Oral precursors offer proven NAD+ elevation, published human trial data, daily convenience, and dramatically lower cost. Until a controlled clinical trial demonstrates that IV NAD+ produces superior long-term healthspan outcomes compared to daily oral supplementation, the oral route remains the evidence-based choice for most people pursuing NAD+ restoration as a longevity strategy.